The artificial cornea is 100% made of non-biological materials and require no co-implantation of donor corneas and it is an ideal option for treating patients with corneal blindness
These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
It provides Covid-19 detection and Omicron surveillance in less than two hours
The tie-up combines Abbisko Therapeutics’ proprietary drug discovery platform with Lilly’s disease and discovery expertise
Prof Karikó's research was most notably used by Pfizer/BioNTech and Moderna to build COVID-19 mRNA vaccines
Prior to IHH, Anurag held senior leadership roles in Fortis Healthcare and Manipal Health Enterprises.
Dr Woler joins Sygnature Discovery after the company received significant investment from Five Arrows Principal Investments, the European corporate private equity arm of Rothschild & Co, in 2021
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
Chicago based virtual reality company reaches AIIMS, assisting in surgical planning and training
Market data indicates that more than twenty percent of the new chemical entities being developed use roller compaction technology in their development and commercialization
Subscribe To Our Newsletter & Stay Updated
